182 related articles for article (PubMed ID: 12851531)
1. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Boström SL; Hansson GF; Kjaer M; Sarich TC
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):457-62. PubMed ID: 12851531
[TBL] [Abstract][Full Text] [Related]
2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
[TBL] [Abstract][Full Text] [Related]
5. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
6. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Eriksson UG; Johansson S; Attman PO; Mulec H; Frison L; Fager G; Samuelsson O
Clin Pharmacokinet; 2003; 42(8):743-53. PubMed ID: 12846595
[TBL] [Abstract][Full Text] [Related]
7. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
8. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
9. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Sarich TC; Teng R; Peters GR; Wollbratt M; Homolka R; Svensson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):485-92. PubMed ID: 12739986
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
[TBL] [Abstract][Full Text] [Related]
13. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
14. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Hellgren M; Johansson S; Eriksson UG; Wåhlander K
BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
[TBL] [Abstract][Full Text] [Related]
15. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Wernevik LC; Nyström P; Johnsson G; Nakanishi T; Eriksson UG
Clin Pharmacokinet; 2006; 45(1):77-84. PubMed ID: 16430312
[TBL] [Abstract][Full Text] [Related]
18. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
[TBL] [Abstract][Full Text] [Related]
19. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Wolzt M; Wollbratt M; Svensson M; Wåhlander K; Grind M; Eriksson UG
Eur J Clin Pharmacol; 2003 Oct; 59(7):537-43. PubMed ID: 12955372
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
